3 High-Yield Dividend Funds Taking Advantage of Market Volatility

Outside of the FAANG bubble, to date in 2018 the U.S. stock market has trended sideways. As you may be aware, that sideways direction has been punctuated by large daily moves in both directions – up and down. Increased market volatility can produce more attractive return opportunities for covered call option traders. However, you don’t have to be an options trader to get a boost from your income stock portfolio based on the covered call strategy.

When you see the financial news media talking about market volatility or the VIX, those metrics are derived from options pricing on the S&P 500. When the market is volatile, option buyers will pay more, and option sellers ask for more to cover the risks of quickly changing share prices. The covered call strategy involves buying shares of a stock and then selling call options backed by the shares. The strategy produces cash income from the call options sales. A cap is put on the upside of potential share price gains, and the options provide a small cushion against a price drop. The covered call strategy is primarily an income producing strategy.

You don’t have to become an options trader to benefit from covered call selling. There are about two dozen closed-end funds that employ the strategy. When you invest in one of these CEFs, you will get exposure to the stock portfolio of the fund, plus an attractive dividend yield from the call selling employed by the fund managers. Here are three funds to consider.

Columbia Seligman Premium Technology Growth Fund (NYSE: STK) seeks capital appreciation through investments in a portfolio of technology related equity securities and current income by employing an option writing strategy.

The fund’s investment program will consist primarily of investing in a portfolio of equity securities of technology and technology-related companies as well as writing call options on the NASDAQ 100 Index or its exchange-traded (ETF) fund equivalent on a month-to-month basis.

The aggregate notional amount of the call options will typically range from 25% to 90% of the underlying value of the fund’s holdings of common stock. Results have been excellent, with annualized returns of 18.4% and 20.9%, for the last three and five years, respectively.

STK currently yields 8.4%.

Eaton Vance Tax-Managed Buy-Write Opportunities Fund (NYSE: ETV) invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Buy-Write is another name for covered call writing. Also, as the fund name states, the managers strive to generate the best after tax returns. The fund uses the S&P 500 stock index as its benchmark evaluate returns.

Three and five year average annual returns have been 11.0% and 13.25 percent respectively. To show that different managers will have their day, ETV is up 6.9% year to date, while STK has gained just 3.2%.

ETV pays monthly dividends and currently yields 8.5%.

BlackRock Enhanced Capital & Income Fund (NYSE: CII) seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. The fund also employs a strategy of selling call and put options.

While the other two funds use index or ETF options for income, the BlackRock managers employ the writing of single stock options. Selling puts is a comparable strategy that can at times produce better returns compared to selling calls.

Three and five year annual returns for CII were 11.9% and 13.8%, respectively. The fund is up 5.25% year to date.

CII pays monthly dividends and yields 6.0%.

Get up to 14 dividend paychecks per month from safe, reliable stocks with The Monthly Dividend Paycheck Calendar, an easy-to-use system that shows you which dividend stocks to pick, when to buy them, when you get paid your dividends, and how much.  All you have to do is buy the stocks you like and tell them where to send your dividend payments. For more information Click Here.


Source: Investors Alley 

7 Alternative Internet of Things Stocks to Buy

Source: Shutterstock

As an investment sector, the Internet of Things, or IoT, is a no-brainer. Increasingly, our consumer devices no longer have a specific function or operation; rather, they’re part of an integrated, digital ecosystem that responds to variable requests. This movement will only increase in volume and engagement, but picking the right IoT stock can be a challenge.

That’s because no single definition of an IoT stock exists. Typically, financial writers focus on big semiconductor names like Micron Technology (NASDAQ:MU) or Intel (NASDAQ:INTC). The connection is readily apparent: these major tech manufacturers produce the physical components that go into IoT devices. But you’re also likely to gain serious profits through investing in renowned device-makers and distributors like Garmin (NASDAQ:GRMN).

Going with the blue chips is the most popular way to pursue an IoT stock. Personally, I have zero complaints about this approach. But I’d also like to give some lesser known or less appreciated IoT companies some love.

It’s a big market, and it’s only going to get bigger. Thus, it’s an opportune time to get acclimated with the other names in the sector.

Here are my choices for the best alternative Internet of Things stocks:

Best Alternative Internet of Things Stocks: Honeywell (HON)

As a multi-faceted organization, Honeywell (NYSE:HON) is probably the most comprehensive IoT stock available in the markets; it just doesn’t get as much coverage as a sector player as you might expect. I find this strange considering that they make common home products, such as thermostats, air conditioners and security systems, that scream IoT.

Honeywell is also a leader in industrial IoT, or IIoT. Again, this is probably one of the lesser-appreciated components of the Internet of Things, which largely focuses on consumer goods. But IIoT has the potential to revolutionize manufacturing as we know it, improving efficiencies, providing real-time data analysis, and reducing the frequency and impact of human error.

The one major knock on HON as an IoT stock is that it’s somewhat of a bellwether investment. In other words, HON is incredibly boring. Plus, shares have generally tracked the broader markets recently, which has produced uninspiring results.

But if you’re not looking for a sexy play and want something stable, HON is one of your top choices.

Best Alternative Internet of Things Stocks: ADT

Best Alternative Internet of Things Stocks: ADT

Source: Shutterstock

I mentioned previously that the most popular IoT stock tends to be either a semiconductor firm or device manufacturer. These are natural choices considering that they’re direct plays. However, IoT also serves a defensive or protective role. That’s why if you love this sector, you should check out ADT (NYSE:ADT).

ADT is a name you immediately recognize, either because you’re enrolled in their security services or you have their sign planted conspicuously on your front yard. Earlier this year, our own Tom Taulli covered ADT and its initial public offering. He provided some background about the company, stating:

“ADT, whose roots go back to 1874, is the most recognized brand in its industry. A survey indicates that it has about 95% awareness with consumers. This is certainly a big-time advantage as the market is highly competitive.

Keep in mind that ADT controls about 30% of the residential market in the U.S. and Canada. In all, there are 7.2 million residential and business customers.”

That sounds spectacular. Unfortunately for early bird investors, ADT is down sharply from its IPO price, as Wall Street reassessed its competitive risks.

ADT is speculative, no doubt about it. Still, with a year-to-date loss of 34%, I like it as a contrarian opportunity.

Best Alternative Internet of Things Stocks: Johnson Controls International (JCI)

Best Alternative Internet of Things Stocks: Johnson Controls International (JCI)

Source: Shutterstock

When we discuss the Internet of Things, we often think small and personal. We consider devices that adjust our home’s temperature automatically, or devices that give us the ability to warm-up our cars from afar. Not to take away from these consumer innovations, but they also limit what IoT can do broadly.

For an IoT stock with a much larger framework, check out Johnson Controls International(NYSE:JCI). While not exactly the most popular household name, Johnson Controls corporate heritage extends back to the 19th century. Today, the company is known for its build-management and safety systems. Additionally, JCI features a battery and distributed-energy storage divisions.

A significant concern about JCI stock, though, focuses on its fundamentals, which are middling. The company has also tacked on more debt, which makes it difficult to invest in future innovations. As a result, JCI shares are down almost 8% YTD.

That said, JCI appears to have found a baseline of support after hitting a year-low in late April. Given its massive resources, and penchant for technological advancements, Johnson Controls is a solid bet.

Best Alternative Internet of Things Stocks: Emerson Electric (EMR)

Best Alternative Internet of Things Stocks: Emerson Electric (EMR)

Source: Shutterstock

Similar to other innovations, some organizations are guilty of using IoT as a buzzword, and nothing else. This reminds me of the blockchain: everybody talks about it, but few understand what it is, and even fewer offer practical solutions with it.

Thankfully, Emerson Electric (NYSE:EMR) rises above the hype, delivering scalable IIoT solutions for the world’s top industries. EMR has particularly found success with large oil and energy corporations as they shift toward next-generation technologies. Moreover, Emerson Electric offers training services to help their clients get the best out of the IIoT movement.

Like many of the names mentioned on this list, EMR stock hasn’t generated much excitement this year. Shares have been choppy, but have so far only broken even. But I expect this circumstance to change. After having some rough years, Emerson Electric is firmly in recovery territory. Last quarter, the company generated $4.25 billion in sales, up nearly 19% YoY.

Best Alternative Internet of Things Stocks: NetGear (NTGR)

Best Alternative Internet of Things Stocks: NetGear (NTGR)

Source: Shutterstock

Computer-networking firm NetGear (NASDAQ:NTGR) has largely earned its reputation through selling popular routers and firewalls. In addition, the company sells storage devices, and owns a security-camera business with its spin-off organization, Arlo. This synergy of connectivity-related expertise makes NTGR one of the more exciting opportunities among IoT stocks.

The evidence lies in its market performance. On a YTD basis, NTGR shares are up over 32%. While I’m not the biggest fan of buying into extreme strength, its fundamentals justify the premium. Definitely, if NTGR stock hits a corrective phase, you should immediately put it on your must-watch list.

For starters, NetGear has demonstrated consistently strong earnings performances. The last time the company failed to meet expectations was back in the second quarter of 2015. Since then, management has beaten their earnings-per-share estimates.

NTGR is a distinct IoT stock in that it has a strong balance sheet with zero debt on its books. That enables its leadership team to invest in research and development, giving it a leg-up on the competition. Finally, the company has enjoyed robust revenue growth, which should continue due to increased sector demand.

Best Alternative Internet of Things Stocks: Analog Devices (ADI)

Best Alternative Internet of Things Stocks: Analog Devices (ADI)

Source: Shutterstock

With a name like Analog Devices (NASDAQ:ADI), ADI doesn’t seem to fit the description of an IoT stock. Yet don’t let initial appearances fool you: Analog Devices have built some of the most groundbreaking semiconductor technologies for commercial industries and scientific endeavors.

What’s more, ADI refreshingly focuses not just on IoT for its own sake, but as a comprehensive solution. Their products and services ensure both technical connectivity, as well as relevant and accurate data analysis and transmission.

According to their corporate ethos, you’re only as strong as your weakest link. Therefore, management expends significant effort to create seamless communication among the “things” of an IoT network.

Another component of ADI’s investment potential is its growth metrics. For instance, its profitability margins are ranked among the best semiconductor firms. The company’s three-year revenue growth rate averages 17.4%, and that doesn’t look to fade anytime soon. In Analog Devices’ last earnings report, it delivered $1.51 billion in sales, up a whopping 32% YOY.

Best Alternative Internet of Things Stocks: Fitbit (FIT)

Best Alternative Internet of Things Stocks: Fitbit (FIT)

Source: Shutterstock

I’ve saved my most speculative idea for an alternative IoT stock for last. Fitbit (NYSE:FIT) captured the wildly popular fitness market’s attention with their quirky advertisements and killer products. When the company first hit its stride, no one could get enough of their fitness trackers. Now, with fierce competition from Garmin and Apple (NASDAQ:AAPL), Fitbit appears merely an also-ran.

As I said in my previous write-up about FIT stock, I don’t blame you if you take that argument. Since its IPO, and especially since its early run-up, FIT has become an unmitigated disaster. Even when shares fell into the teens, and optimists like yours truly considered it a contrarian opportunity, Fitbit still disappointed.

But if you’ve been paying attention, you’ll know that FIT stock dramatically reversed its ugliness. On a YTD basis, shares are up over 15%. Of course, most people regard this as a bull-trap. I think there’s still significant upside remaining.

That’s because Fitbit focuses almost exclusively on fitness trackers, whereas its competitors are encumbered with various and sometimes disparate markets. Furthermore, Fitbit features a popular user ecosystem that’s difficult to replicate.

FIT stock is by no means a sure thing, but it has enough good qualities to justify a calculated risk.

As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities.

Buffett just went all-in on THIS new asset. Will you?
Buffett could see this new asset run 2,524% in 2018. And he's not the only one... Mark Cuban says "it's the most exciting thing I've ever seen." Mark Zuckerberg threw down $19 billion to get a piece... Bill Gates wagered $26 billion trying to control it...
What is it?
It's not gold, crypto or any mainstream investment. But these mega-billionaires have bet the farm it's about to be the most valuable asset on Earth. Wall Street and the financial media have no clue what's about to happen...And if you act fast, you could earn as much as 2,524% before the year is up.
Click here to find out what it is.

7 Top S&P 500 Stocks to Consider for Long-Term Gains

Source: Shutterstock

The S&P 500 is an index containing the largest stocks in the country. Investors use it to gauge how stocks are doing overall, as it serves as a snapshot for the U.S. equities market. Generally speaking, the index is also used as a benchmark, as everyone from retail investors to hedge fund managers compare their performance to it.

With that being said, there are a lot of names in the S&P 500 that investors don’t want to own, simply because they are not performing well. Do you know how unlikely it is to consistently get 500 winners?

In that regard, let’s take a look at how investors can use key stocks held in the S&P 500 to build a winning portfolio over the long term.

Top S&P 500 Stocks to Own: Nvidia (NVDA)

Top S&P 500 Stocks to Own: Nvidia (NVDA)

Perhaps Nvidia (NASDAQ:NVDA) is too obvious a stock to name here. But given its large rally over the past year, many investors feel like they’ve missed the boat.

Admittedly, Nvidia stock has rallied impressively over the past few years, up 53%, 379% and 1,157% over the past 12, 24 and 36 months, respectively. While another 1,000% rally in the next few years is likely out of the cards, there could still be substantial upside in Nvidia. For instance, the stock reaching over $300 in the next six to 12 months isn’t out of the question.

The company has positioned itself as a market leader in a number of secular end markets. Nvidia’s work in artificial intelligence (along with its numerous subcategories like deep learning and machine learning), in gaming chips and in the datacenter is all very impressive. Finally, it would come as a shock if Nvidia wasn’t the biggest winner from the autonomous driving race. While automotive revenue isn’t clocking in with massive growth right now, the self-driving industry is still in the very early innings. As it gains tractions, Nvidia’s DRIVE platforms will play a massive role in the industry.

While Nvidia may trade at 14 times sales, keep in mind it has far better margins than Advanced Micro Devices (NASDAQ:AMD) or Intel Corporation (NASDAQ:INTC). On an earnings basis though, Nvidia’s valuation is much more reasonable. At just 34 times this year’s earnings, that’s not much of a premium for a big-time grower like NVDA.

Analysts expect 34% sales growth this year and 50% earnings growth. While those numbers slow significantly in 2019, my guess is that they’re too conservative. Nvidia hasn’t just topped earnings estimates over the last few years — it has crushed every quarter. Its story isn’t done yet.

Top S&P 500 Stocks to Own: Apple (AAPL)

Top S&P 500 Stocks to Own: Apple (AAPL)

Apple (NASDAQ:AAPL) isn’t very controversial, but it needs to be included.

It’s the largest company in the S&P 500 and for good reason. Apple’s products and brand have made it so millions of customers around the world don’t even consider owning a competing brand. So long as it continues to make a sticky ecosystem, business should continue to do well.

Having a $100 billion buyback shows just how strong those cash flows are each quarter. Impressively, this follows previous buyback plans that ran into the tens of billions as well. More than likely, it comes ahead of many more billions being plowed into future share repurchases. Warren Buffett has made Apple the largest position in his Berkshire Hathaway (NYSE:BRK.A, NYSE:BRK.B) holdings as well.

Apple also pays out a decent dividend, yielding 1.5%.

While shares are near the highs and as its market cap gravitates toward $1 trillion, it’s still one investors should have on their radar. Perhaps use a market-wide correction to initiate a new position.

At 18.5 times this year’s earnings, Apple stock is reasonably priced given its size and status. It’s also reasonable given its growth, even though on its own historical averages, it’s not exactly cheap. Analysts expect sales to grow 14% this year and 4% in 2019. On the earnings front, estimates call for 25% growth this year and 15% growth next year.

Don’t forget about the company’s budding services revenue, which could be a standalone company at this point. Last quarter its $9.2 billion in sales grew 31% year-over-year and came in vastly ahead of analysts’ expectations of $8.4 billion. If that momentum continues, it will help drive AAPL stock higher.

Top S&P 500 Stocks to Own: 3M (MMM)

Top S&P 500 Stocks to Own: 3M (MMM)

3M (NYSE:MMM) hasn’t had the easiest time lately. But I think its business, chart and dividend make it one that certain investors should consider.

For starters, 3M made our list of best dividend stocks just this week. The company has not only paid out a dividend for a whopping 60 years, but it’s also raised its dividend every year for six decades. For income investors, there’s not much more you can ask for in terms of consistency. (The top dividend-payer only has three more years than  3M).

As for its business, estimates call for 5.7% sales growth this year and 3.5% next year. That goes along with 13% earnings growth in 2018 and 9% in 2019. For this, investors are paying about 18 times earnings.

Some will point out that they can buy Apple for a lower valuation with better growth and that’s true. 3M isn’t for all investors. But a look at the charts tells us we have a solid risk/reward opportunity here. Should MMM stay above downtrend resistance near $200, it could mean shares have finally bottomed.

This $190 to $195 area has clearly been support. If 3M can gain some upside traction, it could be attractive going into the second half of the year. Keep in mind, this stock topped out over $250 earlier this year.

Top S&P 500 Stocks to Own: General Motors (GM)

Top S&P 500 Stocks to Own: General Motors (GM)

General Motors (NYSE:GM) may not be a name many would have expected, but the automaker doesn’t seem to get enough credit. With a dividend yield of nearly 4% and trading at 6.2 times next year’s earnings, GM stock is at least one to take a deeper look at.

Admittedly, the automaker does not boast great growth. Analysts expect revenue to grow just 40 basis points this year and 50 basis points next year. On the earnings front, they expect a 3% decline in 2018 and a 0.5% gain in 2019. I find that the expectations for a 3% decline may be a bit aggressive, but either way even if GM reports flat growth, it’s still rather unremarkable.

The stock recently ran from $37 to $45 in just a few days time. That was after SoftBank(OTCMKTS:SFTBY) took a near-20% stake in Cruise Automation, a company that GM bought for roughly $1 billion two years ago.

Based on the deal, that gave an $11.5 billion valuation to Cruise. In other words, GM owns a majority stake in what is now a highly valued asset. Buy low, right? However, despite GM rallying significantly after the SoftBank deal was announced, it’s now falling back down to $39.

That could give investors a great opportunity to get long the automaker at a low valuation and collect a big dividend while they wait. GM can be a big player in the autonomous driving movement, with RBS analysts predicting that it could become a $43 billion enterprise for GM by 2030.

It’s also worth noting is that GM currently has a market cap of $56 billion.

Top S&P 500 Stocks to Own: JPMorgan (JPM)

Top S&P 500 Stocks to Own: JPMorgan (JPM)

JPMorgan Chase (NYSE:JPM) beat on earnings and revenue estimates last Friday. Before that, the bank passed its Fed stress tests and gave a big boost to its capital return plans.

The bank is boosting its quarterly payout to 80 cents a share, up from 56 cents per share before the stress test results. In other words, JPM gave a 43% boost to its dividend and now yields about 2.9% annually. The bank can also buy back almost $21 billion over the next 12 months.

These positive catalysts are beginning to give JPM stock a boost, as shares crossed a vital level on Monday.

Even better, JPM’s valuation and growth profiles are attractive.

Analysts expect revenue to grow 7% this year and another 4% next year. On the earnings front though, estimates call for around 30% growth this year and another 8% growth in 2019. Given that JPM trades at just 16 times this year’s earnings, it makes it mighty attractive.

Top S&P 500 Stocks to Own: Delta (DAL)

Top S&P 500 Stocks to Own: Delta (DAL)

We recently took a closer look at four airline stocks investors might want to buy. Like Apple, the four largest U.S. airline stocks are all owned by investing legend Warren Buffett. Their low valuation, strong cash flow generation and capital return make them attractive. Plus, air travel is becoming more popular than ever.

One to consider from the group is Delta Air Lines (NYSE:DAL). Check out this piece to see our simple table comparing all four names.

While Delta didn’t lead any specific category other than dividend yield, it scored high enough in each measure to be considered one of the best. The company boasts respectable revenue growth and double-digit earnings growth this year and next year.

Paying out a 2.7% dividend yield now, buying back plenty of stock and trading at less than 16 times this year’s earnings makes it too attractive to keep off the list. Unlike some other airline stocks, DAL stock is holding support too.

Now, it just needs to get through $51 and then a 10% rally is in the cards.

Top S&P 500 Stocks to Own: Vanguard S&P 500 (VOO)

Top S&P 500 Stocks to Own: Vanguard S&P 500 (VOO)

I don’t want investors to mistake this article for a Warren Buffett rah-rah piece. But despite his humble approach, it’d be insulting to consider him anything less than an investing king at this point. Whether it has been his investments from three decades ago or how he stepped into the banks during the Great Recession, he will be remembered for eternity. (Well, probably).

In any regard, his top advice for individual investors is to invest in low-cost index funds for the S&P 500. When held over very long stretches, these investments have worked out wonderfully for investors. Throw in the low fees and the returns are better than most individual investors can muster on their own. For instance, the Vanguard S&P 500 ETF (NYSEARCA:VOO) is up 14% over the past year and 32% over the past three years.

While there’s a lot of stocks that have outperformed that and many on this list have done so, there are also plenty of duds that haven’t.

It doesn’t have to be an “either-or” situation though. Investors can use something like the VOO for a core position and, say, a few names on this list to build around it. That way they have the best of both worlds.

Get up to 14 dividend paychecks per month from safe, reliable stocks with The Monthly Dividend Paycheck Calendar, an easy-to-use system that shows you which dividend stocks to pick, when to buy them, when you get paid your dividends, and how much.  All you have to do is buy the stocks you like and tell them where to send your dividend payments. For more information Click Here.


Source: Investors Alley 

 

Big Weed Is About to Collide with Big Money for Even Bigger Profits

Editor’s Note: Michael pushed this out to his free Strategic Tech Investor readers last night. Now that they’ve had the chance to get ready, we want to make sure everyone has a chance to cash in here. To get Michael’s free tech and pot stock investing research for yourself each week, just click here. Here he is…

I knew legal cannabis began to step out of the shadows and onto the big stage when some of its largest and best-run firms started listing on major U.S. stock exchanges.

Two Canadian companies have done that so far – uplisting their OTC-traded stocks to one of the big American exchanges.

At the end of February, Cronos Group Inc. (Nasdaq: CRON) uplisted to the Nasdaq, while Canopy Growth Corp. (NYSE: CGC) debuted on the New York Stock Exchange on May 19.

Both of those were big news at the time.

And for a very good reason, as I’ll show you…

Legal Weed Is Hitting In the Big Leagues Now

Quite simply, these young, aggressive, and above all well-positioned firms are now on the same playing field as some of the top tech names in the world.

That hasn’t escaped the attention of Wall Street.

Drop Everything: Canada just became the first major economy to legalize marijuana nationwide, giving investors a once-in-a-lifetime chance to potentially make millions of dollars from Canadian marijuana companies. Learn more…

You see, fund managers who run $1 billion-plus portfolios are often hamstrung by strict limits on what they can own.

Often, for example, they can only hold stocks that are traded on major exchanges. In other words, fund managers and other big spenders who like these companies now have the green light to buy. We’re talking about pension funds, mutual funds, hedge funds, and more.

That’s a lot of potential buying pressure from institutional investors that should keep interest alive – and money rolling in.

But, for all that, we still haven’t seen a cannabis initial public offering (IPO) on one of the big U.S. exchanges.

Until now…

Pot’s Potential Makes This One of Few IPOs Worth Following

A British Columbia-based cannabis startup – one I’ve been watching for years now – just began marketing its upcoming Nasdaq IPO.

A “roadshow” unlike any other is in the offing.

That means its executives and marketing team have signed up their banking partners… and are hitting the road in order to show (and, of course, sell) its IPO to big-money investors.

It values its IPO at near $1.5 billion – and will make its debut on the Nasdaq Global Select Market exchange.

“In general, U.S. capital markets have generally been closed to growers. [This company] is reflecting that exchanges like Nasdaq and New York [Stock Exchange] are starting to open up to the fact that cannabis is a legitimate marketplace,” Scott Greiper, president and founder of cannabis-focused investment bank Viridian Capital Advisors, said. “Every exchange is looking to be on the front lines of capital markets.”

And that trend is only going to escalate as more U.S. states – and more nations around the world – continue to legalize cannabis.

This seed-to-sale cannabis company has a long history of being a “first mover” in its sector. Not only is it the first marijuana company to IPO on a major U.S. exchange, but it was the first Canadian cannabis company to distribute its marijuana at home and internationally.

That gives it entry into not only the $4.7 billion Canadian market, but the international market as well. That market is expected to reach $57 billion by 2027, according to Arcview Market Research – and some analysts believe it could reach $1 trillion in short order.

When this company makes its debut, it’ll complete the perfect “Big Weed” triple-play, along with Cronos and Canopy Growth – two pot stocks I recommend accumulating here.

Canada’s Cannabis Billions Could Be Unleashed, Potentially Overnight

Now, I’ve already laid out my case for this soon-to-be public Canadian company in a special report that’s free to select members of my Radical Technology Profitsservice. You can click here to learn how to get it.

I told those subscribers that it’s the “Canadian cannabis IPO I’m watching closest right now” – and that was before the Nasdaq news broke.

But the truth is, weed investing is about more – much more – than a promising IPO.

Just to give you an idea of the potential here, by 2027, it’s expected that about 40% of all legal marijuana across the globe will be sold in Canada. All told, Canada’s total legal weed market – when you add in the growers, the value-added product makers, the testing labs, security, tourism, exports, and all the rest – could soon reach $22.6 billion, according to Deloitte.

Those incredible statistics cannot be understated.

And they’re why I believe investors should be focusing their attention on Canada-based marijuana companies and stocks, like Cronos and Canopy Growth.

I can’t believe this “surfer dude” beat all those Wall Street legends... ​650 of the world’s biggest and brightest minds... I’m talking about legends like Mario Gabelli... David Einhorn... Joel Greenblatt... and Rick Rieder... who, combined, manage more than $5 trillion. All were forced to bow down to one “unheard of” trader from Laguna Beach. Click Here to discover the strategy he used while he had sand between his toes.

Source: Money Morning 

Are Options Traders Telling Us To Stay Away From Emerging Markets?

If you’ve been reading my articles regularly, you’ll know that I spend a lot of time talking about block trades.  These are the huge trades that show up on your options volume screeners, typically in increments of 1,000 or bigger.  They can be unusual volume in a normally lightly traded name, or they may be very big trades which occur in high volume names (such as index ETFs).

Options analysts like to look at block trades to see where the action is.  Usually very big trades are executed by traders with abundant capital.  Of course, lots of capital usually means access to copious amounts of research as well.  In other words, block trades are often done by people who have very good information.

Many times, the reasons behind these really big trades are easy to figure out.  Hey, someone bought 20,000 calls in Apple (NASDAQ: AAPL), it’s probably going up!  Or, sheesh, someone bought 50,000 puts in SPDR S&P 500 ETF (NYSE: SPY), it’s probably a hedge against a correction!

Other times, trying to figure out the purpose of a block trade can be a puzzle.  Sometimes, you never know what the traders are trying to accomplish.  It’s not like we are seeing the actual trading books of these traders… just one big trade at a particular point in time.

Still, there is a lot that can be gleaned from watching block trades, especially in stocks and ETFs which don’t trade that often.  They may give you an idea of where the underlying asset is headed or if volatility is going to pick up, among other things.

Here’s a very interesting block trade I came across this week…

The trade involved the purchase of over 20,000 puts on Invesco Emerging Markets Sovereign Debt ETF (NYSE: PCY).  Now, an emerging market debt fund may not sound all that interesting to you, but there are some very unusual factors to consider regarding this trade.

First off, PCY is a fund that buys government debt in emerging market countries.  It’s got about $4.5 billion in assets, making it the second largest ETF in this space.  However, the largest fund in the emerging market debt space is far bigger.  In fact, iShares JP Morgan USD Emerging Market Bond ETF (NASDAQ: EMB) has $12.5 billion in assets.

And that’s not all…

Not only is EMB the more popular fund, it’s also much more heavily traded.  Average daily options volume in EMB is about 10,500.  In PCY, the average is 8.  That’s right… 8 options per day.  When over 25,000 options trade in one day in an ETF that normally averages 8, it definitely draws attention.

In this case, it wasn’t actually one huge block trade, but several smaller blocks of the September 27 puts (with the stock around $27.25).  When you have a name like PCY which isn’t liquid in options, you may see the trade broken into many smaller parts to get it filled.  And sure enough, there were lots of pieces traded, from roughly 200-lots up to 1000, with prices ranging from around $0.60 to $0.80… mostly purchases.

This would lead us to believe the trader (or traders) think the ETF is going down by the end of the summer.  That in turn means there’s a fair amount of money (something like $1.5 million) betting that emerging market government bonds are going to take a hit in the coming weeks.  You can see form the chart that PCY has been on a sharp run higher the last week or so.

This leads to several questions….

If it’s a hedge against a downturn in emerging market debt, why not use the much more liquid EMB options?  For that matter, even from a speculation standpoint, you could probably get better fill prices on EMB options.  Their implied volatilities were about the same at the time of the trades, so it doesn’t seem to be a relative value proposition.

I can think of two reasonable explanations, although I’m sure there are others I’m not considering.  First off, the trade could have to do with the actual bond holdings of the particular ETFs. On the surface, it looks like PCY and EMB have similar exposure to countries and credit ratings groups. But, drilling down may show one has more or less exposure to a potential default candidate.

(For the bond nerds out there, EMB does have quite a bit shorter duration than PCY, but that’s probably not much of a difference maker.  Perhaps more importantly, EMB has over 400 bonds in its portfolio while PCY has just over 100.)

The other potential explanation is more nebulous.  Perhaps there’s something about the actual structure of the PCY ETF which is amiss.  It may be that someone very smart has figured out that given the structure of the bond portfolio, the ETF price should be lower than it is.  That’s not the sort of thing I can prove, but we should know by September if PCY drops more than EMB.

No matter the reason, it may not be a bad idea to take a flier on PCY puts, especially if you’re bearish on emerging market debt.  After all, we have all kinds of tariffs to consider which could hurt emerging market countries.  And, the debt problems in Italy could spill over into emerging market bonds as well.  For under $0.75 a put, it’s not a bad gamble to make for those looking at something a bit more speculative to trade.

  [FREE REPORT] Options Income Blueprint: 3 Proven Strategies to Earn More Cash Today Discover how to grab $577 to $2,175 every 7 days even if you have a small brokerage account or little experience... And it's as simple as using these 3 proven trading strategies for earning extra cash. They’re revealed in my new ebook, Options Income Blueprint: 3 Proven Strategies to Earn Extra Cash Today. You can get it right now absolutely FREE. Click here right now for your free copy and to start pulling in up to $2,175 in extra income every week.

1 Click to Boost Your Dividend Income 59%

It’s a question I get from investors all the time: “Should I take my dividends in cash or reinvest them through a dividend reinvestment plan (DRIP)?”

My answer: unless you want your cash sitting in your account earning zero, your best bet is to reinvest any dividend money you don’t need to pay your bills.

But we don’t want to practice “buy and hope” investing, either, whether we do it through obsolete DRIPs or the old-fashioned way.

When I say “buy and hope,” I mean putting your cash into household names like the so-called Dividend Aristocrats and “hoping” for higher stock prices when you cash out in retirement.

You’ve probably heard of the 53 stocks on the Aristocrats list, which have raised their payouts for at least 25 straight years. Trouble is, despite their lofty name, these companies hand us a pathetic current dividend of 2.2%, on average.

And many pay a lot less:

5 Dividend Paupers

So if you invest mainly in these stocks (as many people do), you won’t have to worry about reinvesting your dividends. You’ll need every penny of dividend income just to keep the lights on!

That’s because even with a $1-million portfolio, you’re only getting $22,000 in dividend income a year here, on average. That’s not far above poverty-level income for a two-person household.

Pretty sad after a lifetime of saving and investing.

Luckily, there’s a way we can rake in way more dividend cash. I’m talking a steady $75,000 a year in income on a million bucks. And if you’re not a millionaire, don’t worry: a $550k nest egg will bring in $41,200 annually, enough for many folks to retire on.

That’s 59% more income than our million-dollar Aristocrat portfolio, from a nest egg that’s a little over half the size!

How to Bank an Extra $41,200 in Cash Every Year

I know what you’re thinking: “Brett, that amounts to a 7.5% yield. There’s no way a payout like that can be safe.”

You can be forgiven for thinking that, because you hear it everywhere (heck, even my financially savvy personal trainer didn’t believe payouts like this were possible).

But the truth is, there are plenty of safe payers throwing off at least that much, like the 19 stocks and funds I recommend in my Contrarian Income Report service (which I’ll show you when you click here).

Right now, these 19 sturdy investments yield 7.5%, on average. And every month I personally run each one through a rigorous dividend-safety check, starting with 3 things that are absolutely critical:

  1. Rising free cash flow (FCF)—unlike net income, which is an accounting measure that can be manipulated, FCF is a snapshot of how much cash a company is making once it’s paid the cost of maintaining and growing its business;
  2. A payout ratio of 50% or less. The payout ratio is the percentage of FCF that went out the door as dividends in the last 12 months. Real estate investment trusts (REITs) use a different measure called funds from operations (FFO) and can handle higher payout ratios, sometimes up to 90%;
  3. A healthy balance sheet, with ample cash on hand and reasonable debt.

Making DRIPs Obsolete

The best part is, these 19 investments are perfect for dividend reinvestment because each one gives us a dead-giveaway signal of when it’s time to buy, sit tight—or sell and look elsewhere for upside to go with our 7.5%+ income stream.

That makes DRIPs obsolete!

Because why would we mindlessly roll our dividend cash into a particular stock every quarter when, at a glance, we can pinpoint exactly where to strike for the biggest upside?

To show you what I mean, consider closed-end funds (CEFs), an overlooked corner of the market where dividends of 7.5% and up are common. We hold 11 CEFs in our Contrarian Income Report portfolio, mainly larger issues with market caps of $1 billion or higher.

(By the way, my colleague Michael Foster focuses 100% on CEFs in his CEF Insider service, where he keys in on funds with sub-$1-billion market caps trading at ridiculous discounts due to their obscurity. That sets you up for fast 20%+ upside and dividends up to 9.4%. You can check out a recent interview I did with Michael here.)

We don’t have to get into the weeds, but CEFs give off a crystal-clear signal that a big price rise is coming. You’ll find it in the discount to NAV, which is the percentage by which the fund’s market price trails the market value of all the assets in its portfolio.

This number is easy to spot and available on pretty well any fund screener.

This makes our plan simple: wait for the discount to sink below its normal level and make your move. Then keep rolling your dividend cash into that fund until its discount reverts to “normal.”

That’s exactly what we did with the Nuveen NASDAQ 100 Dynamic Overwrite Fund (QQQX) back in January 2017—and the results were breathtaking.

How We Bagged a 42% Total Return (With a 7.5% Yield) in 15 Months

QQQX is run by portfolio manager Keith Hembre, who cherry picks the best stocks on the NASDAQ, juices their high yields with a safe options strategy, then dishes distributions out to shareholders.

It’s hard to imagine now, after the huge run tech stocks have put in over the past couple years, but back in January 2017, QQQX was trading at a 6% discount to NAV and paid a 7.5% dividend.

That triggered our initial move into the fund. And over the next 15 months, we bagged two dividend increases and watched as QQQX’s discount swung to a massive premium—so much so that by the end of that period, the herd was ready to ante up $1.13 for every buck of assets in QQQX’s portfolio!

Discount Window Slams Shut…

That huge swing from a discount to a premium catapulted us to a fat 42% gain (including dividends). But the fund’s outrageous premium meant its upside was pretty well maxed out by the time we took our money off the table on April 6, 2018.

… and Delivers a Fast 42% Gain

And what’s happened since?

QQQX has moved up slightly—a 1% gain. But that’s way behind the market, which has cruised to a 7.5% rise.

Premium Gives Us the Perfect Exit

Forget QQQX: Grab These 8% Monthly Dividends Instead

Luckily, the herd has cooled a bit on QQQX, but it still trades at a 5% premium to NAV. And why the heck would we overpay when the ridiculously inefficient CEF market is throwing us bargain after bargain as I write this?

And there’s one more thing I have to tell you: many of these cheap CEFs pay dividends monthly instead of quarterly.

So if you hold them in your retirement portfolio, their massive dividend payouts will roll in on exactly the same schedule as your monthly bills!

Convenience isn’t the only reason to love monthly payers, though. Because they also let you reinvest your payouts faster, amplifying your gains (and income stream) as you do.

I’m talking about an automatic “set-it-and-forget-it” CASH machine here!

  [FREE REPORT] Options Income Blueprint: 3 Proven Strategies to Earn More Cash Today Discover how to grab $577 to $2,175 every 7 days even if you have a small brokerage account or little experience... And it's as simple as using these 3 proven trading strategies for earning extra cash. They’re revealed in my new ebook, Options Income Blueprint: 3 Proven Strategies to Earn Extra Cash Today. You can get it right now absolutely FREE. Click here right now for your free copy and to start pulling in up to $2,175 in extra income every week.

10 Dividend Stocks That Will Double Your Money

Is it possible to double your money – quickly – buying safe dividend stocks? You bet. Let me explain how…

“Basic” income investors are enamored with higher current yields. These are OK for payouts today, but they’re not going to get us 100%+ gains.

For triple-digit profits we must pay attention to the underrated dividend hike. These raises not only increase the yield on your initial investment, but they trigger stock price increases, too.

For example, if a stock pays a 3% current yield and then hikes its payout by 10%, it’s unlikely that its stock price will stagnate for long. Investors will see the new 3.3% yield and buy more shares. They’ll drive the price up, and the yield back down – eventually towards 3%.

This is why many Dividend Aristocrats don’t pay high current yields: Their prices just rise too fast. Just look at A.O. Smith (AOS), which perpetually yields in the low 1% range. The low yield isn’t from a lack of dividend hikes – in fact, AOS keeps hiking its payout more aggressively over time. But investors just keep chasing the stock too high!

A.O. Smith (AOS): A Boring Company With a Breathtaking Trajectory

What a “problem” to have!

If you’re looking for a “dividend stock double” to bring you secure gains of 100% or better, consider these ten payers. Don’t be fooled by their modest current yields – these dividends will probably always look modest thanks to soaring share prices.

American States Water (AWR)
Dividend Yield: 1.7%

I’ll start off with American States Water (AWR) delivers water up and down California – an absolutely necessary service that its 1 million-plus customers can’t go without. That results in a steady stream of revenues and income – profits that tick higher over time as American States Water slowly raises rates. It’s a well-worn utility story.

What’s a little less common about AWR is its absurd growth.

American States Water (AWR): Is This a Utility … Or a Chip Stock?

Up next for AWR? The company likely will announce its 64th consecutive dividend increase sometime in very early August.

Dover Corporation (DOV)
Dividend Yield: 2.6%

American States Water may have an impressive dividend-growth streak, but it’s not actually a member of the Dividend Aristocrats given its small-cap nature and exclusion from the S&P 500. But Dover (DOV) is full-fledged dividend royalty, touting an equally impressive streak of 62 consecutive years – the longest streak among Aristocrats and the third-longest among all publicly listed companies.

Dover is a widely diversified industrial company whose products range from product-tracing technologies to bench tools to chemical dispensing systems to commercial refrigeration units. That kind of product breadth has allowed the company to weather even the worst economic environments with the dividend not only intact, but growing each and every year.

As a note: A look at a Dover chart shows a big dip in May. Don’t worry. This wasn’t the effect of a nasty earnings surprise, but instead a reflection of the spinoff of Apergy (APY), its oil-and-gas equipment-and-technology business.

Consecutive dividend hike No. 63 should be announced sometime during the first full week in August.

First American Financial Corporation (FAF)
Dividend Yield: 3.0%

Trying to get decent yield from a financial stock is like trying to wring blood from a monkey wrench. The Financial Select Sector SPDR Fund (XLF) exchange-traded fund of banks, insurers and other financial companies yields a miserable 1.6%. That’s why it’s refreshing to come across companies such as First American Financial Corporation (FAF).

FAF sounds like a bank, but it’s actually a top title insurance and settlement services provider used by real estate and mortgage companies. And, like similar companies, it offers a wide array of other products, from home warranties to property and casualty insurance to even investment advice.

First American’s dividend increase schedule has been a little variable over the past five years, but it manages to get the job done at some point. The best bet for FAF’s next increase announcement is sometime in mid-August, with the payout itself coming a month later.

Brinker International (EAT)
Dividend Yield: 3.1%

Brinker International (EAT) isn’t nearly as recognizable a name as the brands that it owns – specifically, Chili’s and Maggiano’s Little Italy restaurants, which combine for more than 1,600 locations worldwide.

Brinker had been struggling mightily amid the “restaurant recession” of the past few years that saw giant chain restaurants but together a huge string of monthly same-store sales declines. Brinker itself delivered a couple disappointing earnings reports that sent investors fleeing EAT shares.

That said, the company is back on the rebound in 2018 as various changes, including a heavily scaled-back menu, are bearing fruit. Brinker scored a beat in its most recent quarterly report (in May), and while same-store sales dipped a bit, the company still is tracking a potential growth year in comps.

Brinker also has been upgrading its dividend for several years now, and given a payout ratio of just more than half its profits, chances are EAT investors will enjoy another dividend-hike announcement sometime in the middle of August.

Chili’s Parent Brinker International (EAT) Tries to Reach Recovery Road

Federal Realty Investment Trust (FRT)
Dividend Yield: 3.2%

Federal Realty Investment Trust (FRT) is a virtual unicorn – a real estate investment trust (REIT) in the Dividend Aristocrats. In fact, at the moment, it’s the only real estate play in the whole hallowed group.

Despite what the name would imply, Federal Realty isn’t a government-real-estate play – it’s a mixed-use retail REIT that focuses on high-end properties in Washington, D.C.; Boston; San Francisco and Los Angeles. To give you an example, FRT is responsible for Pike & Rose – a commercial/dining/living mixed-use development in North Bethesda, Maryland, that includes tenants such as Pinstripes (a bowling-and-bocce bistro), L.L. Bean, REI Co-Op and four apartment-and-condominium communities.

FRT has grown its dividend every year since 1972, from 7.3 cents to its current payout of $1 per share. The next hike should come in either very early August or the tail end of July.

Healthcare Trust of America (HTA)
Dividend Yield: 4.5%

Healthcare Trust of America (HTA) is one of many “Boomer” plays – this one dubbing itself the “largest dedicated owner & operator of medical office buildings in the country.” Specifically, it owns 432 medical office buildings across 33 states covering just about every region in the U.S. minus “Big Sky” country.

I love niches, I love specialties, and HTA has a fairly interesting one. This REIT has specifically targeted between 20 and 25 “gateway markets” that have top university and medical institutions, which means they’re more likely to be hotbeds of future facility growth. That’s smart.

The downside is, so far, while it has led to excellent growth in funds from operations (FFO), it hasn’t led to riches for shareholders, who are sitting on essentially flat performance since 2015.

Healthcare Trust of America (HTA): What Is Wall Street Waiting For?

But HTA is among a few stocks that have seen recent insider buying – a promising sign of confidence from people who are in the know and have real skin in the game. Maybe that’ll be the kick in the pants the stock needs.

Investors also could use a more robust dividend bump than they’re accustomed to. Healthcare Trust’s income growth has been glacial – just 6.1% total over the past five years. Look to see if management is any more generous sometime during early August or very early July, when the company is likeliest to announce its next dividend top-off.

Verizon (VZ)
Dividend Yield: 4.6%

Telecom titan Verizon (VZ) has been a sleepy disappointment in 2018, off 5% year-to-date against a higher market. You can thank a few things for that – an uber-competitive pricing environment for telcos, an earnings disappointment at the beginning of the year, and sluggishness in its Fios video offerings.

It could be worse. AT&T (T) is off by about 15% as Wall Street voices its skepticism over the Time Warner acquisition.

Verizon remains a stable dividend play, however, delivering a yield well north of 4% on a payout-growth streak of 11 years. No. 12 likely will be announced late in August or in the first couple days of September.

Altria Group (MO)
Dividend Yield: 4.8%

We’ve been told for years that tobacco stocks would be miserable investments thanks to increasingly strict government bans on cigarette use and dwindling consumers as anti-smoking campaigns continue to take root. Yet Marlboro maker Altria Group (MO) mostly managed to swim upstream for many years.

But the stock has seemingly come up against a ceiling, peaking a couple of times in 2017 before succumbing to an eventual downtrend. Altria’s earnings report from April tells a lot of the tale – the company still is squeezing out ever-higher profits, at $1.9 billion versus $1.4 billion in the year-ago period. But sales ticked up just a half a percent, and domestic cigarette shipping volumes actually declined by more than 4%.

A 17% decline in 2018 has juiced Altria’s dividend to nearly 5%, however – but so has a dividend hike announced on March 1. That was actually outside the company’s routine, which is to announce any increases in late August. It’s very possible that the hike was The company typically

Altria actually hiked the dividend once this year, from 66 cents to 70 cents per share, but it did so away from its normal dividend-hike schedule. So Altria is actually a stock to watch here in late August – namely, to see whether the company resumes its routine with a summertime dividend improvement, or simply delivered early.

Main Street Capital (MAIN)
Dividend Yield: 5.9%

I have a love-hate relationship with Main Street Capital (MAIN)I love this business development company’s ability to execute, but I hate how expensive the stock typically is! Few BDCs are run as well as Main Street Capital, but you really have to pick your spots.

As a reminder: BDCs help finance small- and midsize businesses. In Main Street’s case, they provide capital for lower and middle-market companies. Their target company has revenues between $10 million and $150 million, and EBITDA between $3 million and $20 million, and Main Street typically will invest anywhere between $5 million and $75 million.

Main Street is one of a few good actors in the space, and its long-term performance reflects that. In fact, MAIN has nearly quadrupled the broader VanEck Vectors BDC Income ETF (BIZD) in total returns over the past five years.

Main Street Capital (MAIN) Is Among the Best in This Brutal Biz 

While many BDCs have stagnant dividends, Main Street Capital’s payout keeps ticking higher, even if it’s just by a little bit year after year. The company should announce its next set of monthly payouts at the very beginning of August or the end of July – and there should be a slightly higher number attached to them.

Buckeye Partners LP (BPL)
Distribution Yield: 14.7%

Buckeye Partners LP (BPL) might have the highest yield of any company on this list, but it’s not a product of a hyper-aggressive dividend-growth problem. BPL is earning its yield the wrong way: hemorrhaging shares. The stock is off nearly 60% since mid-2014, in fact, not rebounding with much of the rest of the energy space.

Buckeye Partners is mostly split into two parts – about half of its profits comes from domestic pipelines and terminals, while most of the rest comes from global marine terminals. Despite this diversified business, BPL keeps running into hurdles, such as losing a large storage customer in 2017.

The company has gone so far as to abandon its practice of increasing dividends every quarter, thanks to extremely tight dividend coverage. That having been said, the company still has a 22-year streak of annual dividend increases it probably wants to extend, so it’s entirely possible that Buckeye Partners will offer up a token hike in the first week of August – roughly a year since its last dividend increase.

Lock In 100%+ Dividend Growth Returns

If you want a healthy retirement portfolio, it’s absolutely vital that you stuff it with dividend growth stocks. High-yield stocks with stagnant payouts will actually lose value over time, and your regular income checks won’t stretch as far as they used to thanks to inflation drag. But dividend growth stocks will not only keep you ahead of inflation – they’ll help grow your nest egg, too!

Because, like I showed you with A.O. Smith, the very best dividend stocks will rise in line with their increasing payments.

Most people never realize this. But those of us who DO stand to profit handsomely and almost automatically!

It’s a simple three-step process:

Step 1. You invest a set amount of money into one of these “hidden yield” stocks and immediately start getting regular returns on the order of 3%, 4%, or maybe more.

That alone is better than you can get from just about any other conservative investment right now.

Step 2. Over time, your dividend payments go up so you’re eventually earning 8%, 9%, or 10% a year on your original investment.

That should not only keep pace with inflation or rising interest rates, it should stay ahead of them.

Step 3. As your income is rising, other investors are also bidding up the price of your shares to keep pace with the increasing yields.

This combination of rising dividends and capital appreciation is what gives you the potential to earn 12% or more on average with almost no effort or active investing at all.

I’ve scoured thousands of stocks out there right now, looking for the very best companies that have both rising dividends and strong buyback programs in place … the kind of stocks that could easily spin off annual total returns of 12%, 17%, even 25% or more … doubling your money in very short order.

Right now, at this very moment, there are 7 in particular that I think you should consider buying.

They stand to do well no matter what the broad market does … regardless of what happens in Washington … and irrespective of interest rate trends.

Editor's Note: The stock market is way up – and that’s terrible news for us dividend investors. Yields haven’t been this low in decades! But there are still plenty of great opportunities to secure meaningful income if you know where to look. Brett Owens' latest report reveals how you can easily (and safely) rake in 8%+ dividends and never worry about drawing down your capital again. Click here for full details!

10 Strong Buy Stocks for Under $10

Source: Shutterstock

Just because a stock is cheap doesn’t mean you should have to compromise on quality. These 10 Strong Buy stocks tick all the boxes. True, they are all trading for under $10, but they also represent compelling investing opportunities based on far more than just their price. I used TipRanks’ stock screener to purposefully scan for stocks with a Strong Buy consensus rating from analysts and top analysts alike. These are stocks with a bullish Street outlook based only on the last three months of ratings.

I then ordered the results by price in order to delve deeper into the cheaper stock results. I am confident that these 10 stocks provide intriguing investing opportunities for investors. You don’t need to spend over $1,000 on a large-cap stock with a big name to generate serious investing returns. I hope these stellar stock ideas will show you why.

Let’s take a closer look now:

Strong Buy Stocks: Rigel Pharmaceuticals (RIGL)

Strong Buy Stocks: Rigel Pharmaceuticals (RIGL)

Source: Shutterstock

Our first Strong Buy stock pick Rigel Pharmaceuticals (NASDAQ:RIGL) is also the cheapest. Trading at just $2.98, this biotech offers investors massive upside potential of over 165%. This would take shares to $7.90, the average analyst price target. Most recently, HC Wainwright’s Joseph Pantginis reiterated his Buy rating with a $7.50 price target.

He cites two key bullish factors supporting his rating: 1) the potential for Rigel to expand R835 into multiple autoimmune disorders, including arthritis and MS; and 2) the ramp up of newly-approved drug Tavalisse for adults with chronic immune thrombocytopenia (ITP). This is a dangerous disorder that can lead to excessive bleeding and bruising.

According to Pantginis, Tavalisse is “making early strides.” He notes that the drug is still in the “show-me” stage of launch for investors. However, the early signs are promising. The drug is priced competitively and it has the backing of a comprehensive commercial strategy. This includes educating physicians on the significant clinical benefits of Tavalisse vs. current treatments and maximizing awareness and access for patients.

Overall, five analysts have published Buy ratings on RIGL in the last three months.

Strong Buy Stocks: Glu Mobile (GLUU)

Strong Buy Stocks: Glu Mobile (GLUU)

Source: Shutterstock

San-Francisco based Glu Mobile (NASDAQ:GLUU) is most famous for its slew of celebrity mobile app games. Ever heard of Kim Kardashian: Hollywood? This was GLU’s handy-work. However, the company is much more than just a one-hit wonder, according to Piper Jaffray’s Michael Olson. He has initiated coverage on GLUU with a $7.50 price target (19% upside potential). The stock is currently trading at $6.31.

“We now see a path to continued multiple expansion and margin improvement based on the changes implemented to date,” the analyst said. “While new titles are less critical for the ongoing growth of the business than was historically the case, Glu does have a solid pipeline of new games that are expected to hit in [the second half of 2018] and 2019.”

And while these new releases are encouraging, Olson is most enthusiastic about GLUU’s existing user base: “This data allows the company to better allocate resources to content updates that will drive monetization; it also creates a widening competitive barrier to entry vs. many other mobile developers.”

Right now, four analysts have Buy ratings on the stock. This is based only on ratings from the last three months.

Strong Buy Stocks: Resonant (RESN)

Strong Buy Stocks: Resonant (RESN)

Source: Shutterstock

Small-cap tech stock Resonant (NASDAQ:RESN) is a designer of filters for radio frequency (RF) front-ends for smartphones. This is basically the circuitry in mobile phones for analog signal processing. And the stock is on the cusp of big growth according to the Street.

Five-star Loop Capital analyst Cody Acree sees RESN exploding by a whopping 107%. He has initiated coverage with a Buy rating and $11 price target. “We believe the company continues to make significant fundamental customer and design win progress that should begin delivering material recurring royalties through the remainder of 2018”, writes Acree.

Specifically, he is a fan of the company’s unique Infinite Synthesized Network platform technology. This is “a software-based, high-precision modeling approach that is able to produce real-world testable results in a completed design”, explains Acree. Customers can now eliminate software design flaws before wafer production begins.

The best part is that this should prove much more “attractive to the market than the traditional method of running multiple physical iterations through a wafer fab”. Indeed, RESN boasts four recent Buy ratings from the Street. These analysts have an average price target of $8.25 (55% upside potential).

Strong Buy Stocks: Achaogen (AKAO)

Strong Buy Stocks: Achaogen (AKAO)

Source: Shutterstock

Achaogen (NASDAQ:AKAO) now looks like a very compelling investing opportunity, as this cheap Strong Buy stock just got cheaper. And now is the perfect time to jump in.

AKAO develops innovative antibacterials to treat multi-drug resistant infections. At the end of June its Zemdri drug received regulatory approval for the treatment of complicated urinary tract infections. However, this prompted a sell-off. Investors were disappointed that the drug did not also receive approval for CRE bacteria infections.

But analysts quickly reiterated their support of AKAO, calling the sell-off “excessive.” “We see the sell-off in AKAO from already markedly discounted levels as overdone and see attractive opportunity”, writes Cowen & Co’s Chris Shibutani. He says this is what he expected in terms of the timing and label following the advisory review. Plus, this is by no means the end of the road for AKAO and CRE. “We expect real-world use in CRE even in the absence of a formal label given clinical/microbial data”, adds Shibutani. He reiterated his Buy rating without a price target.

However, we can see that other analysts are predicting massive upside potential of 144%. This would take AKAO from $7.78 to the $19 average price target. In total, the stock has received six buy ratings vs. just 1 hold rating in the last three months.

Strong Buy Stocks: Zynga (ZNGA)

Strong Buy Stocks: Zynga (ZNGA)

Source: Shutterstock

Social game developer Zynga (NASDAQ:ZNGA) has just snapped up Gram Games for $250 million in cash. This makes the stock even more attractive to investors. London-based Gram Games has two key franchises in the hyper-casual and puzzle genres: Merge Dragons! and 1010Merge Dragons! is particularly promising with the potential to become a forever franchise.

Indeed, top Jefferies analyst Timothy O’Shea is certainly bullish on the deal. He writes: “It is another acquisition straight out of the Zynga playbook: acquire established mobile franchises at a reasonable multiple, and apply sophisticated user acquisition, analytics, and live services know-how to increase profitability and extend the life of the games.”

Even better, “The deal is immediately accretive and we think it makes sense to deploy cash towards EBITDA-generating M&A vs. leaving cash on the balance sheet.” With this in mind, he ramps up his 2019 bookings & EBITDA estimates by 9%. He also boosts his price target to $5.25 (24% upside potential) from $5 previously.

Five analysts have published Buy ratings on Zynga in the last three months, with just one analyst staying sidelined.

Strong Buy Stocks: GenMark (GNMK)

Strong Buy Stocks: GenMark (GNMK)

Source: Shutterstock

GenMark Diagnostics (NASDAQ:GNMK) develops state of the art molecular diagnostic testing systems. Its eplex system has just been released and it has already won an award for medical design excellence. Right now, the system can only test for and identify the most common respiratory viral and bacterial organisms. However, other panels in development will test for blood diseases, gastrointestinal bacteria and central nervous system infections.

All eyes are currently on the recent blood disease regulatory submission. “We are positive on GNMK following the submission of its blood culture ID gram positive (BCID-GP) panel to the FDA, which comes in line with expectations”, writes top Canaccord Genuity analyst Mark Massaro. “We view GNMK’s submission to the FDA as a de-risking event.” He is now more confident that GenMark can generate meaningful ePlex revenue outside of its respiratory panel in 2019.

And long-term, the prospects are even more exciting: “We continue to believe that GNMK can penetrate the multi-billion-dollar global multiplex syndromic testing panel market with multiple ePlex test panels over time.” This five-star analyst has a $9 price target on the stock (29% upside potential). Three analysts have published recent GNMK Buy ratings with a $10.33 average price target.

Strong Buy Stocks: Ferroglobe Plc (GSM)

Strong Buy Stocks: Ferroglobe Plc (GSM)

Source: Shutterstock

Ferroglobe PLC (NASDAQ:GSM) is among the world’s largest producers of silicon metal. Silicon is a critical ingredient in a host of industrial and consumer products with growing markets. In the chemical industry it is used in photovoltaic solar cells and electronic semiconductors. And aluminum manufacturers use it to improve the already useful properties of aluminum. When used with aluminum, silicon improves its flexibility, hardness and strength.

With demand dynamics on its side, the company is a bargain at just $8.30. Indeed, three analysts have published recent Buy ratings on GSM. This is with a very bullish $16.33 average analyst price target. From current levels that indicates upside potential of 97%. Plus management has just initiated an interim quarterly dividend of 6-cents-per-share (2.1% yield), reflecting confidence in the underlying business.

Strong Buy Stocks: Cleveland-Cliffs (CLF)

Strong Buy Stocks: Cleveland-Cliffs (CLF)

Source: Shutterstock

From silicon let’s turn to the world of iron ore. Cleveland-Cliffs (NYSE:CLF) is buzzing right now with shares shooting up over 26% in the last three months. But this success story isn’t slowing down, in fact its just beginning. Top B. Riley FBR analyst Lucas Pipes has just ramped up his price target from $11 to $12 (41% upside potential).

He cites higher domestic steel prices, higher iron ore prices and a robust pellet premium — all of which are likely to boost 2018 EBITDA and cash-flow expectations. “Longer-term, the robust price backdrop holds the potential to improve the outlook of Cliffs’ existing domestic iron ore mines and ongoing HBI development”, writes Pipes.

And shareholders should note that capital return could be on the agenda. CLF also mentioned it may establish a dividend, but if this comes it will be in 2019. Management intends to generate about $100M in 2018 FCF while 2019 should be ~$200M. Pipes concludes: We remain upbeat on growth project, strategic direction and valuation.

Overall, CLF has received five recent buy ratings with a $10.30 average analyst price target (21% upside potential).

Strong Buy Stocks: Seres Therapeutics (MCRB)

Strong Buy Stocks: Seres Therapeutics (MCRB)

Source: Shutterstock

Biotech Seres Therapeutics (NASDAQ:MCRB) is a perfect stock for any bargain hunters. The company is focused in the emerging field of microbial medicine. Basically, Seres is trying to treat infectious and inflammatory diseases by adding “good” bacteria to your digestive tract.

“We believe the company is well positioned to take advantage of their pioneering efforts in understanding microbiome biology and applying those learnings to human disease management”, writes top Cantor Fitzgerald analyst William Tanner. He has a $16 price target on the stock (73% upside potential). He isn’t concerned about regulatory setbacks as investors should “recognize that the results could provide clues as to how the course could be corrected.”

According to Tanner, SER-401 could be where the pipeline sizzle is. Seres is developing SER-401 to impact the immune response and increase the efficacy of inhibitors in cancer treatment: “Evidence has been emerging that the microbiome may play an important role in immune system modulation.” Seres plans to initiate clinical testing of SER-401 in 2018.

With four recent buy ratings, the $18 average analyst price target indicates over 95% upside potential.

Strong Buy Stocks: LendingClub (LC)

Strong Buy Stocks: LendingClub (LC)

Source: Shutterstock

Our tenth cheap stock pick comes from the financial sector. U.S.-based LendingClub (NYSE:LC) is one of the first peer-to-peer lending companies. While the stock has previously given investors a choppy ride, the future looks more stable according to five-star BTIG analyst Mark Palmer. He has a $7 price target on the stock (58% upside potential).

“Investors should be more optimistic about reduced volatility in LC’s operating performance in coming quarters”, advises Palmer, adding that they should also “be less pessimistic about how the company’s marketplace lending platform would fare if a repeat of the market dislocations seen in 2016 were to occur.”

Palmer has just met with CEO Scott Sanborn who stressed how the funding model has become much more diversified. This makes the company much more resilient. “This newfound resilience was due in large part to the introduction of new sources such as securitizations and CLUB certificates — pass-through securities holding a basket of loans — that provided LC with access to a new group of large institutional investors”, explains Palmer.

LendingClub has 100% Street support right now. Five analysts have published recent Buy ratings with a $5.80 average price target (32% upside potential).

Get up to 14 dividend paychecks per month from safe, reliable stocks with The Monthly Dividend Paycheck Calendar, an easy-to-use system that shows you which dividend stocks to pick, when to buy them, when you get paid your dividends, and how much.  All you have to do is buy the stocks you like and tell them where to send your dividend payments. For more information Click Here.


Source: Investor Place

This Tax “Loophole” Boosts Your Dividends to 9.5%

Still feeling the taxman’s sting from April? Then you probably need to consider getting some tax-free income.

Having an income stream the IRS can’t touch may sound like pie in the sky, but it’s a reality if you hold municipal bonds. That’s because the tax code provides an exclusion for these bonds, allowing most US investors to collect interest payments from them tax-free. And in many states, income from those bonds is exempt from state taxes, as well.

If you aren’t intrigued yet, then let me show you some numbers—and what they could mean to your portfolio.

If you’re in the highest tax bracket (37%) and you get a 6%-yielding municipal-bond fund, that income is the exact same as a 9.5% dividend from stocks. And municipal bonds are nowhere near as volatile as high-yield stocks. Just compare the volatility of the iShares National Muni Bond ETF (MUB) and the Vanguard High Dividend Yield ETF (VYM):

A Smoother Ride Makes Withdrawals Easier

Not only does this lower volatility give you peace of mind, but it also makes withdrawing from your principal easier in cases of emergency.

There’s just one problem—MUB yields a paltry 2.4%!

But have no fear—I’m going to show you 3 closed-end funds (CEFs) that yield far more than that and are still tax-free. Before I get to them, though, let me tell you why you should choose these funds, and why now is the time to jump in.

Why Muni CEFs—and Why Now

One of the biggest benefits of closed-end funds is how inefficient they are. It sounds crazy, but CEFs cater to retail investors, who often just don’t know how far apart these funds’ market prices are from their their net asset values (NAVs), resulting in big discounts for a lot of CEFs.

In fact, the average CEF now trades at a 6.3% discount to its NAV—which is near the biggest average discount over the last year.

But some CEFs are more heavily discounted than others, while some actually trade at a premium—or for more than what their portfolios are worth. That risk of overpaying is why you can’t just choose any CEF.

The most interesting trend in CEFs over the last few months has been the shrinking discount to NAV among equity funds and the growing discount among bond funds—but nowhere is the discount bigger than among municipal-bond funds. Take a look:

Big Discounts in Muni Funds Create Buying Opportunities

Source: CEF Insider

With the average discount among muni-bond CEFs at 8.6% (which is near double the 5.3% average discount of just a year ago, by the way), these funds offer us an incredible buying opportunity right now.

And while a few discounts in US-stock CEFs are still there, the recovering market that I predicted back in April means that the oversold equity funds I showed you back then aren’t so cheap anymore, so we need to get a bit creative.

Which is why muni-bond funds are the “it” thing to buy right now.

For one, with their unusually large discounts, muni funds are finding it easier to sustain their dividend payments, providing us with a safer income stream. Also, despite popular belief, municipal bonds do not go down during periods of rising interest rates.

In fact, this “rates up, muni bonds down” myth is a big driver of why muni-bond CEFs are so cheap now, again giving contrarians like us an opportunity to get tax-free income at a heavy discount.

Don’t believe me? Take a look at this chart from the mid-2000s, when the Federal Reserve increased interest rates by over 400%:

Interest Rates Rise—and so Do Muni Bonds

That blue line is the Invesco Municipal Opportunity Trust (VMO), the first pick I want to show you today. It’s a 5.7% yielder full of tax-free muni bonds that went up a full 17% during the last sustained rate-hike cycle.

And it’s unusually cheap now: its 10.8% discount to NAV is massive on its own, but it’s even more attractive when you consider that VMO’s discount has averaged just 2.3% in the last decade.

On top of that, VMO is managed by Invesco, one of the world’s biggest fund companies, with over $950 billion in assets under management (AUM). So you can count on this fund being reliable and secure.

Additionally, VMO has a long history. It’s been around since the early ’90s and has delivered consistently strong results since then—surviving the dot-com bubble bursting, the subprime mortgage crisis and all the drama in between:

A Steady Long-Term Performer

Which brings me to my second big yielder worth considering: the PIMCO NY Municipal Income III Fund (PYN), a 5.9% payer managed by one of the most respected names in the bond world: PIMCO, with $1.8 trillion in assets under management—more than the GDP of several small countries!

PIMCO built those assets through outperformance, which is why most of the company’s CEFs tend to trade at premiums to NAV.

PYN, however, is different. With a 2.6% discount to NAV, this fund is trading for less than the value of the assets in its portfolio—something it hasn’t done since 2009! And there’s no reason for it to trade so cheap, since PYN has doubled the return of its benchmark, MUB, since the Federal Reserve started raising interest rates in late 2015:

A Huge Overachiever

With such a track record, expect this one to trade at a premium to NAV soon. But there’s one other thing that makes PYN attractive: its size, or lack thereof.

Because PYN has just $51 million in AUM, it’s simply too small for a lot of large institutional investors—and that small size means that it’s incredibly inefficient, even by CEF standards. That’s why this fund typically has traded for a premium to NAV for most of the last decade, making its recent discount that much more appealing.

The last fund I want to show you is the BlackRock Municipal Income Investment Trust (BBF), which commands attention thanks to its 6.1% yield.

But that’s not the best thing about this fund. Like PYN, BBF is really small, with just $142.2 million in AUM, which is about a quarter of the size of most muni CEFs. And that small size results in mispricings that don’t reflect its stellar track record.

Another Big Winner

As you can see, the BlackRock Municipal Income Investment Trust has beaten the index for a very long time (this chart just covers five years, but since the fund’s inception in 2007, BBF has returned 79.3% versus MUB’s 50% over the same period).

I may be burying the lead here, though; the really nice thing about BBF is its manager: BlackRock, the largest investment firm in the world, with a staggering $6.3 trillion in assets under management. That means it has the connections to get the best municipal bonds as soon as they go IPO, the best minds and technology to analyze those municipal bonds and the best market position to trade those bonds most profitably.

Is this corporate heft priced in to BBF? Hardly. It’s trading at a massive 7.4% discount to NAV, after trading at a premium for most of the last three years:

BBF Suddenly Very Cheap

Should we expect this premium to NAV to come back? The short answer is yes. The discount only showed up—and steepened—in the last few months due to the market panic of the last few months.

But the market is getting more comfortable, which will likely result in BBF returning to its normal high price—giving those of us who buy today some tidy capital gains on top of that massive 6.1% income stream.

This CEF Doubled the Market and Pays 7.8% in Cash!

There’s no doubt that in a few months we’ll look back at the selloff in muni bonds and recognize it for the terrific buying opportunity it was. So don’t miss your chance to lock in the safe, tax-free payouts muni-bond funds offer now—while you can still get them cheap.

Here’s something else you should know: “munis” aren’t the only assets to be hit by the silly (and wrong) investor myth that rising rates are a bad-news story.

Another? High-yield real estate investment trusts (REITs).

And just as I showed you with VMO above, REITs also do great when rates head higher—contrary to what most folks believe.

Check out how the benchmark REIT ETF, the Vanguard REIT ETF (VNQ) did in the last sustained rising-rate period:

Rates Rise, REITs Surge

That makes now a terrific time to buy this unloved asset class, too. But just as we did with muni-bond funds, we’re going to take a pass on the popular REIT ETF and go with my top CEF pick in the sector.

Why?

For one, my No. 1 REIT CEF pick fund hands us an outsized 7.8% CASH dividend today. And talk about stable: it not only survived the financial crisis, it rebounded far more quickly than the market and has gone on to hand investors far bigger gains since.

An All-Star Management Team in Action

And keep in mind that this fund posted these incredible returns while investing in real estate: the very thing that caused the collapse in the first place!

Think about that for a moment.

This fund not only more than DOUBLED the market’s gain—even when you factor in the Great Recession and the subprime mortgage crisis—but its incredible management team did it while paying a rock-solid 7%+ dividend the whole time!

If this isn’t a fund worth paying a premium for, I don’t know what is. But thanks to the wacky mispricings in CEF land, this one’s trading at an absurd discount to NAV today.

Once the herd catches on to what it’s missing, this fund could easily blow into premium territory.

How do I know? Because it’s happened many times in the past—and when it does again, we’ll easily be sitting on an easy 20% gain, on top of this fund’s juicy 7.8% dividend payout.

Please don't make this huge dividend mistake... If you are currently investing in dividend stocks – or even if you think you MIGHT invest in any dividend stocks over the next several months – then please take a few minutes to read this urgent new report. Not only could it prevent you from making a huge mistake related to income investing, it could also help you earn 12% a year from here on out! Click here to get the full story right away. 

Source: Contrarian Outlook 

Sell These Drug Retailers About to Get Amazoned

There has been no company like Amazon.com (Nasdaq: AMZN) ever with the ability to affect entire industries just by announcing its entry.

The most recent example of this was in late June when Amazon announced a roughly $1 billion acquisition of PillPack, a mail-order pharmacy that packages pills into daily portions before shipping them to patients in 49 states.

PillPack was backed by several well-known investors including Silicon Valley venture capital firms Accel and Menlo Ventures. Its target market is people with chronic illnesses or multiple conditions who take several different tablets every day, rather than people who take a single medication or use prescription drugs only occasionally.

Amazon already captures more than $4 out of every $10 spent online in the U.S. So in response to its PillPack announcement, about $14 billion magically disappeared from the stock market valuations of the biggest players in the U.S. drug distribution and retailing. Shares in those six companies – Walgreens Boots Alliance (Nasdaq: WBA)CVS Health (NYSE:CVS)Express Scripts Holding (Nasdaq: ESRX)Cardinal Health (NYSE: CAH)McKesson (NYSE: MCK) and AmerisourceBergen (NYSE: ABC) had already been depressed last year when Amazon hinted that it was coming into their territory. Proof positive trimmed their values by as much as 10%.

Related: Sell These Stocks As Amazon’s Doctor Will Soon Bring Back House Calls

Already the fear of Amazon’s entry into the sector had started a frenzy of consolidation in the sector including CVS agreeing to acquire health insurer Aetna for $69 billion in December, and in March Cigna, a rival health insurer, agreed to pay $67 billion for the aforementioned Express Scripts, a pharmacy benefits manager that also delivers medication by mail.

Amazon’s Long Game

There is one characteristic I’ve always liked about Jeff Bezos and Amazon – its planning for the long-term. This is so unlike most U.S. companies that are focused on the very short-term.

The PillPack purchase looks like a crucial part of a strategy that Amazon has been slowly building brick by brick, and likely just one step of many in the sector it has long eyed.

Its interest goes back to 1999 when it bought a minority stake in Drugstore.com, but never fully integrated it into its core retail offering. Walgreens later bought the website and eventually shut it down in 2016. More recently, Amazon has pursued pharmacy licenses in several US states, held meetings with healthcare industry executives and made several senior hires from insurers and pharmacy benefits managers. And of course, it also recently joined with JPMorgan Chase and Berkshire Hathaway to create a not-for-profit healthcare company that aims to reduce bills for their employees and “potentially all Americans”.

In buying PillPack, Amazon is sticking with the same game plan it is following in the grocery business and its Whole Foods purchase. That is, acquire a company with an existing footprint in a market rather than trying to build a brand new business within its existing retail network. With this purchase, Amazon buys regulatory permits and contracts with health insurers.

While mail order deliveries represent a small proportion of the overall prescription market, it is seen as a source of growth due to demographics – an aging U.S. population will require higher levels of medical care in coming years.

The acquisition should create another competitive advantage for Amazon over others in the space thanks to its extensive logistics network and loyal customer base to its Prime subscription (with 100 million subscribers) delivery service. Amazon may bundle its prescriptions with other products where people make regular, frequent purchases, such as groceries. That could help attract even more Prime subscribers, who spend more and order more frequently from Amazon than non-Prime customers.

Related: Sell These Healthcare Middlemen About to Get Amazoned

But it will not be an easy road for Amazon. That’s because the trend in the pharmacy business is going in the opposite direction of other retail businesses. Last year, about 88% of prescriptions filled were collected at brick-and-mortar pharmacies. That compares to 82% in 2009, according to Goldman Sachs.

As to why this is happening, it’s simple. . .existing mail-order pharmacies stink. For example, with Express Scripts it can take eight days to have a prescription filled and up to two weeks for a new prescription to be filled. Obviously, Amazon is hoping its strength in logistics will shorten those times greatly.

But its logistics won’t help with another problem – about 30% of prescriptions result in a “pharmacy callback”. That is when the medicine prescribed to a patient is not covered by their insurance and the pharmacy then has to contact the doctor’s office to see if a cheaper alternative is acceptable. Perhaps that is why Amazon is pursuing the insurance angle with JPMorgan and Berkshire Hathaway.

Investment Implications

This move into the drugstore space looks to be another win for Amazon. And a loss for the drug distributors and especially the retail drugstores. After all, Amazon is already undercutting them on the prices for non-prescription medicines.

According to Jeffries Group, median prices for over-the-counter, private-brand medicine sold by Walgreens Boots Alliance and CVS Health were about 20% higher than Basic Care, the over-the-counter drug line sold exclusively by Amazon. Amazon began selling the Basic Care line last August with roughly 35 products and has since expanded its range to 65 medicines including mild painkillers, cold and flu medication, sleeping aids and other medication commonly found in the pharmacy aisle. Many of these meds are available through Amazon Prime.

Take all of these moves by Amazon into the distribution of medicines and you have one more reason to sell the drug retailers or, if you’re an aggressive trader, short them.

 

Buffett just went all-in on THIS new asset. Will you?
Buffett could see this new asset run 2,524% in 2018. And he's not the only one... Mark Cuban says "it's the most exciting thing I've ever seen." Mark Zuckerberg threw down $19 billion to get a piece... Bill Gates wagered $26 billion trying to control it...
What is it?
It's not gold, crypto or any mainstream investment. But these mega-billionaires have bet the farm it's about to be the most valuable asset on Earth. Wall Street and the financial media have no clue what's about to happen...And if you act fast, you could earn as much as 2,524% before the year is up.
Click here to find out what it is.

Stock Research Made Simple